An expanded access programme to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 ("COVID-19") induced Acute Respiratory Distress Syndrome ("ARDS"), an immediately life-threatening condition
Latest Information Update: 06 Apr 2020
At a glance
- Drugs DMI 9523 (Primary)
- Indications Adult respiratory distress syndrome
- Focus Expanded access; Therapeutic Use
Most Recent Events
- 02 Apr 2020 According to an Ampio Pharmaceuticals media release, additional information about the potential suitability of the anti-inflammatory properties of Ampion being used for this clinical indication (ARDS) is included in a companion white paper summary titled, "Rationale and scientific evidence for the use of Ampion in the treatment of Acute Respiratory Distress Syndrome secondary to SARS-COV-2".
- 02 Apr 2020 According to an Ampio Pharmaceuticals media release, the company's application to the FDA for a clinical study of Ampion to treat COVID-19 induced ARDS was featured on a FOX NEWS segment titled, "Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug", reported by an affiliated television station in Denver, Colorado.
- 30 Mar 2020 New trial record